ABSTRACT
The viral lineages reflecting variants of concern have emerged worldwide and among them B.1.1.7 (Alpha), B.1351 (Beta) and B.1.617.2 (Delta) variants are the most significant ones and merit close monitoring. In Pakistan, very limited information is available on the circulation of these variants and only the alpha variant has been reported as the main circulating lineage. The objective of this study was to detect and explore the genomic diversity of B.1.351 and B.1.617.2 during the third wave in the indigenous population. During the current study, a total of 2274 samples were tested on real-time PCR for the presence of SARS-CoV-2 from May 14 to May 31, 2021, and among these, 17% were spike positive, whereas 83% of samples had the spike gene target failure (SGTF). From these spike positive samples, 22 samples were processed for whole-genome sequencing. Among VOCs, 45.5% (n=10) belonged to B.1.351 followed by B.1.617.2, 36% (n=8). The delta variant cases were reported mostly from Islamabad (n = 5; 63%) followed by Peshawar and Azad Kashmir (n = 1; 13% each). Beta variant cases originated from Islamabad (n=5; 56%), Peshawar (n=2; 22%), Azad Kashmir and Rawalpindi (n=1; 11% each). The mutation profile of delta variant isolates reported significant mutations, L452R, T478K, P681R, and D950N. The beta variant isolates reported characteristic mutations, D215G, K417N, E484K, N501Y, and A701V. Notably, a characteristic mutation, E484Q was also found in delta variant, B.1.617.2. Our current findings suggest detection of these VOCs from the local population and warrants large-scale genomic surveillance in the country. In addition, it provides timely information to the health authorities to take appropriate actions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received for any part of this work
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Internal Review Board of National Institute of Health, Pakistan
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos